Biohaven
NEWS
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
It was a busy week for clinical trial updates. Here’s a look.
It was a busy week for clinical trial updates. Here’s a look.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
It was a very busy week for clinical trial news. Here’s a look.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Biohaven Pharmaceutical announced positive topline data from its Phase III trial of oral rimegepant (Nurtec) for preventing migraine headaches in both episodic and chronic migraine patients.
JOBS
IN THE PRESS